Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

• Published in: Blood 2021-11, Vol.138 (Supplement 1), p.1535-1535
• Main Authors: Liapis, Konstantinos, Papadopoulos, Vasileios, Vrachiolias, George, Stavroulaki, Emily, Misidou, Christina, Kourakli, Alexandra, Galanopoulos, Athanasios, Papoutselis, Menelaos Konstantinos, Papageorgiou, Sotirios, Diamantopoulos, Panagiotis T, Pappa, Vassiliki, Viniou, Nora-Athina, Tsokanas, Dimitris, Vassilakopoulos, Theodoros P., Hatzimichael, Eleftheria, Koumpis, Epameinondas, Papathanasiou, Konstantina, Bouronikou, Eleni, Ximeri, Maria, Pontikoglou, Charalampos, Megalakaki, Aikaterini, Zikos, Panagiotis, Panayiotidis, Panayiotis, Dimou, Maria, Karakatsanis, Stamatis J., Vardi, Anna, Kontopidou, Flora, Charchalakis, Nikolaos, Adamopoulos, Ioannis, Papadaki, Helen A., Symeonidis, Argiris, Ioannis, Kotsianidis
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2021-149630

Introduction: Less than 5% of patients with MDS present with thrombocytopenia as an isolated abnormality (MDS-IT). There have been few systematic studies on MDS-IT and data regarding its course and prognosis are conflicting. Previous studies have defined MDS-IT based on the IPSS thresholds (Hb ≥10 g/dL; ANC ≥1.8×10 9/L; PLT 12 g/dL (women), and ANC ≥1.8 ×10 9/L, registered in the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes which includes 2792 patients (analysis cut-off date; July 7, 2016). Patients were divided into 4 groups: group 1 had PLT 149-100 ×10 9/L; group 2, 99-50 ×10 9/L; group 3,